Sezen, Celal Bugra, Dogru, Mustafa Vedat, Gokce, Anil, Tanrikulu, Gamze, Sonmezoglu, Yasar, Demirkol, Yasemin Ece, Kilimci, Umut, Erduhan, Semih, Bayraktar, Oguzhan, Erdogu, Volkan, Saydam, Ozkan, and Metin, Muzaffer
Objectives: Our aim in this study was to evaluate the impact of lymph node metastases and histopathological subgroups on survival in patients with resected lung adenocarcinoma. Methods: We retrospectively evaluated a total of 172 patients with invasive adenocarcinoma who were operated on between January 2011 and December 2018. Nodal status was determined according to the number of involved lymph node stations (single or multiple). Results: A total of 141 men (82%) and 31 women (18%) were included in the study. The 5-year survival rate was 37% overall and 72.2% for papillary adenocarcinomas (p=0.041). In patients with pN1a and pN2 disease, 5-year survival rates were 43.6% and 22.1%, respectively (p=0.020). In multivariate analysis, pN2 disease and not receiving adjuvant therapy were identified as poor prognostic factors (hazard ratio=2.02, p=0.019; hazard ratio=0.2, p<0.001, respectively). Conclusion: The results of our study showed that patients with multiple pN1 lymph node metastases have similar survival outcomes to patients with pN2 disease. Most importantly, the main prognostic factor associated with poor survival was pN2 lymph node metastasis. Therefore, we believe that pN1 lymph node status should be evaluated as a separate subgroup in future staging systems. [ABSTRACT FROM AUTHOR]